Join our virtual hereditary cancer webinar series to connect with and learn from leaders in hereditary breast and ovarian cancer research and treatment. Register here.
Who We Are
The Peter Gilgan Centre for Women’s Cancers is a virtual program located at Women’s College Hospital (WCH), which supports patient-centred cancer care in partnership with WCH’s Surgical and Gynecology Services, Medical Imaging, Specialized Medicine Services, the Genetics and Hereditary Breast Cancer Clinic and the After Cancer Treatment Transition (ACTT) Clinic.
The Centre draws together excellence in research, clinical care, innovation and education for women’s cancers. Our team is driven by a powerful vision to give every woman every chance to access the highest standard of cancer care no matter where she lives in Canada.
We are working to make changes in the lives of people touched by women’s cancers by offering patient-centred care at all stages, providing training for health care professionals, empowering individuals with the information they need throughout their cancer journey and revolutionizing care through groundbreaking research.
What We Do
Our clinics at WCH, in partnership with The Centre, offer access to screening and prevention, resources, tools, services and educational materials to empower patients with the information they need. These clinics provide access to diagnosis for breast, endometrial, cervical and thyroid cancers, they perform preventative surgeries for breast and ovarian cancer and offer long-term aftercare, surveillance and support for cancer patients.
In collaboration with these clinics, we are committed to supporting patients through their cancer care journey. Our priorities are to help individuals reduce their risk of getting cancer, diagnose symptoms that are suggestive of cancer, provide access to screening so we can detect cancer early and offer wrap-around support after a diagnosis.
- Programs & Clinics
Support & Education Groups
Brochures & Pamphlets
- Pelvic Health After Breast Cancer (.pdf)
- Talking With Your Children About A Cancer Diagnosis (.pdf)
- What You Need To Know: Preventative Surgery to Remove your Fallopian Tubes and Ovaries (.pdf)
- A guide to BRCA1 and BRCA2 gene mutations in hereditary breast and ovarian cancer
- A guide to talking about BRCA mutations
- Recovering from surgery: What you need to know after having your ovaries and fallopian tubes removed
- Strategies to support a loved one with a breast cancer diagnosis – Facebook Live
Virtual Hereditary Cancer Series
Learn about the latest advances in breast and ovarian cancer research from leaders in the field by joining our virtual, free, one-hour lunchtime seminars. Click the link above to register.
Research & Innovation
Programs & Institutes
A Study of Familial Breast Cancer in BRCA Mutation-Negative Families: Women with a strong family history of breast cancer, but no BRCA1 or BRCA2 mutation, are two to four times more likely to develop breast cancer than women without a family history. Despite this elevated risk, no clinical guidelines have been developed for the care of these women. This study evaluates factors which may influence their risk.
Breast Cancer Treatment in Women with PALB2 Mutations: The Familial Breast Cancer Research Unit at Women's College Hospital is conducting a research study to better understand breast cancer treatment among women with a PALB2 gene mutation.
Cognition in BRCA1 and BRCA2 Mutation Carriers: We are currently recruiting individuals to participate in a study investigating the effects of prophylactic oophorectomy (surgical removal of an ovary or ovaries) on cognition over a three-year period. The purpose of this study is to evaluate possible changes in memory and attention and to determine if there is any correlation with another gene, apolipoprotein E (APOE).
Follow-up Telephone Genetic Counselling Study: This research study aims to evaluate a follow-up telephone-based genetic counselling intervention for women with a BRCA1 or BRCA2 mutation who have received genetic counselling in the past.
Rapid Genetic Testing for Newly Diagnosed Breast Cancer Patients Phase II: This study provides genetic testing for nine genes associated with increased risk of breast and other cancers free of charge to participants. Test results are available quickly, with a testing turnaround time of 5-12 days, and all results are disclosed to participants by a genetic counsellor.
Reducing the bUrden of Breast cancer in Young women (RUBY) Study: This study is a pan-Canadian collaborative comprised of a national network of 62 researchers and clinicians at 44 institutions and clinics across Canada, with the common goal of studying breast cancer in young women.
Risk Factor Analysis of Hereditary Breast and Ovarian Cancer: This is the largest long-term study of women who carry a mutation in one of the two breast cancer genes (BRCA1/BRCA2). Its purpose is to better understand the prevention and treatment of hereditary breast and ovarian cancers.
The Screen Project: The Screen Project is a Canadian National initiative to make BRCA1 & BRCA2 screening available to all Canadians over 18 years of age at an accessible price. We hope that our study will reduce the mortality from breast, ovarian, prostate and other cancers.
- Barrie and Community Family Health Team
- The BETTER Program
- Canadian Cancer Society
- Canadian Cancer Society – Cancer Connection
- Cancer Care Ontario Indigenous Navigators
- ReThink Breast Cancer
- Women’s College Academic Family Health Team
- Women’s College Research Institute
- The Women’s College Hospital Institute for Health System Solutions and Virtual Care